Who are Fibrogen's investors?

Fibrogen's investors include Avalon BioVentures, Ridgeback Capital, Scientia Ventures, Maverick Ventures.

How much funding has Fibrogen raised?

Fibrogen has disclosed $20M raised across 1 round.

Where is Fibrogen headquartered?

Fibrogen is headquartered in San Francisco, US.

Fibrogen

San Francisco, US · 4 known investors

Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.

BiotechHealthtech

Founders & leadership

Frank H. ValoneNamed on SEC filing

Thomas F. KearnsNamed on SEC filing

K. Peony YuNamed on SEC filing

Jorma RouttiNamed on SEC filing

Miguel MaderoNamed on SEC filing

Rory B. RiggsNamed on SEC filing

Toshinari TamuraNamed on SEC filing

Kalevi KurkijarviNamed on SEC filing

Julian N. SternNamed on SEC filing

Thomas B. NeffNamed on SEC filing

James A. SchoeneckNamed on SEC filing

Pat CotroneoNamed on SEC filing

Investors · 4

Avalon BioVenturesSan Diego

Ridgeback CapitalMiami

Scientia VenturesNew York

Maverick VenturesreportedSan Francisco · $3M – $10M

Reported raises · per SEC filings

Form D private placements

$20M disclosed across 1 round · 2014

▶$20MraisedDec 2014 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Frank H. ValoneExecutive Officer
Thomas F. KearnsDirector
K. Peony YuExecutive Officer
Jorma RouttiDirector
Miguel MaderoDirector
Rory B. RiggsDirector
Toshinari TamuraDirector
Kalevi KurkijarviDirector
Julian N. SternDirector
Thomas B. NeffExecutive Officer, Director
James A. SchoeneckDirector
Pat CotroneoExecutive Officer
Roberto Pedro RosenkranzDirector

Offering amount: $20M
Amount sold: $20M
First sale: Nov 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Fibrogen do?: Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.
Who are Fibrogen's investors?: Fibrogen's investors include Avalon BioVentures, Ridgeback Capital, Scientia Ventures, Maverick Ventures.
How much funding has Fibrogen raised?: Fibrogen has disclosed $20M raised across 1 round.
Where is Fibrogen headquartered?: Fibrogen is headquartered in San Francisco, US.